ALIM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Alimera Sciences to ANI Pharmaceuticals
June 24, 2024 09:21 ET
|
Wohl & Fruchter LLP
We are investigating the fairness of the proposed sale of Alimera Sciences to ANI Pharmaceuticals for $5.50 per share in cash, plus a CVR.
Alimera Sciences Proposes Public Offering of Common Stock
August 10, 2016 16:01 ET
|
Alimera Sciences, Inc.
ATLANTA, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a pharmaceutical company that specializes in research, development and commercialization of...
Alimera Sciences announces clinical presentations and sponsored Symposia at ASRS 2016 Annual meeting
August 09, 2016 07:30 ET
|
Alimera Sciences, Inc.
ATLANTA, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today...
Alimera Sciences to Report Fourth Quarter 2015 Financial Results on March 2, 2016
February 18, 2016 07:30 ET
|
Alimera Sciences, Inc.
ALPHARETTA, Ga., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Alimera Sciences (NASDAQ:ALIM), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today...